Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,065 total articles
Nvidia's cash flow and dominance in AI infrastructure underpin a tradeable setup. Entry around $216, stop $203, target $265 — mid-term (45 trading days) — risk/reward skewed in favor of upside given FCF, low leverage, and still-healthy technicals despite short-term momentum softness.
Silvercorp combines steady mine production in China, a strong PEA for its Condor gold project, and a reaffirmed dividend as silver demand tightens. Market cap sits at $2.6B with a 52-week range of $3.57-$15.77. This trade targets a return to the $15 area over the next 45 trading days, with a disciplined stop to limit downside risk.
Calumet (CLMT) is showing signs of a structural earnings lift driven by Specialty Products & Solutions and renewable-fuel catalysts. With recent revenue momentum, DOE support for SAF, improving technicals and a manageable free cash flow profile, a mid-term long trade targeting $42 is a practical, risk-controlled way to capture upside while acknowle…
Radcom (RDCM) is a profitable, cash-heavy provider of cloud-native network intelligence and service assurance. Recent results show steady revenue growth (2025 revenue $71.5M, +17.2% YoY), record operating margins and $109.9M cash with no debt. The business sells into long telco procurement cycles; that makes the stock a patient, fundamentally suppo…
Booking Holdings (BKNG) has been punished this year on fears around AI disruption, competition and geopolitics, yet the business still generates ~$9.0B in free cash flow, trades near $161, and sits well below its 52-week high of $233.6. For patient traders, a disciplined long entry offers asymmetric upside with a clear stop and measured targets.
Palantir just reported blowout growth and margins that read like a software winner. The stock is expensive, but fundamentals and improving commercial traction argue for an aggressive long entry. This trade lays out entry, stop, target, time horizon, catalysts and balanced risks for a long-term (180 trading days) swing into PLTR.
TransMedics (TMDX) sold off after a recent earnings surprise, but the company's core organ-care franchise continues to produce strong unit growth, solid free cash flow and attractive valuation ratios versus future growth. This trade idea proposes a tactical long into the weakness with a clear entry, stop and target and a mid-term horizon to let the…
Canada Nickel offers a high-beta play on nickel exposure with a dense calendar of de-risking milestones. For disciplined traders, a long exposure using tight risk controls captures near-term upside from technical re-ratings and longer-term optionality if project execution and permitting stay on track.
ServiceNow has been punished this year amid growth and margin worries, but recent guidance and early signs of AI product monetization make a defined long trade attractive. Market cap near $105B, meaningful free cash flow, low net leverage and a concentrated short book create a favorable risk/reward for a mid-term bounce to $130. Trade plan, catalys…
Sandisk looks expensive at face value: $1477 stock price, a ~49x P/E and price-to-sales north of 16. But dig into margins, cash flow and the AI-driven demand curve, and the premium starts to make sense. I lay out an actionable long trade with entry at $1480.00, a $2000.00 target and $1250.00 stop, and explain the key catalysts and risks that should…
Aeluma's integrated photonics and quantum dot laser roadmap has a string of recent catalysts - a NASA award, a $4M government contract, and a senior Intel hire - that make the company a plausible beneficiary of rising AI data-center interconnect demand. The business is early, revenue is minimal, and valuation already prices a lot of future growth. …
Duos Technologies (DUOT) has pivoted from rail-imaging hardware into Edge Data Centers and AI-driven recurring services. The stock is extended, but the company’s 2025 revenue surge, recent capital raises and a clear deployment plan create a tradable long opportunity for investors willing to stomach execution and dilution risk. Entry $12.28, target …
Contemporary Amperex Technology (CATL) remains the dominant thematic play on electrification. Financial line items were not available at publication, so this trade idea leans on operational drivers, capacity rollout signals and market dynamics. I recommend a defined long with clear entry, target and stop for a swing-to-position time frame.
Grab trades near its 52-week low despite accelerating revenue and margin progress. With a $14.4B market cap, improving adjusted EBITDA and product momentum from recent AI initiatives, we like a mid-term long that pays off if mobility recovers or financial services continue to scale. Entry $3.50, stop $3.10, target $4.50 over 45 trading days.
British American Tobacco (BTI) looks attractively priced for an income-oriented long trade. At $65.35 the stock offers a c.4.7% yield, a 14x P/E and clear margin/cash generation to support dividends and buybacks while the business transitions to smoke-free formats. Technicals show bullish momentum and a reasonable risk/reward with a stop below $60.…
RTX offers a classic dual-cycle setup: a defensive tailwind from higher missile and air-defense demand plus a recovering commercial engine business. Valuation at ~33x 2026 EPS and an EV/EBITDA near 20 is full but not unreasonable given free cash flow of $8.46B. Trade plan: enter at $177.04, stop $165.00, target $205.00 over a mid-term (45 trading d…
TORM offers a rare combination for income-oriented traders: a >6% yield, activist/strategic shareholder activity and a valuation that reads cheap on simple multiples. Pair that with a recent stretch of operational outperformance and upcoming dividend flow and you have a tradeable long with clear entry, target and stop. This is a tactical position f…
TMC the metals company (TMC) is a high-risk, high-reward play on deep-sea polymetallic nodules that contain nickel, cobalt, copper and manganese. With a new Allseas contract, favorable regulatory momentum and a market cap of $2.34B that represents only a sliver of the company's cited NPV of its resources, now is an actionable dip to take a measured…
Immunovant (IMVT) is upgraded to Buy after recent evidence and corporate moves that increase the probability IMVT-1402 becomes a multi-indication FcRn franchise. The setup combines a crowded but expanding autoimmune market, upcoming near-term readouts (RA topline expected H2 2026) and improved technical momentum. This is a high-risk, potentially hi…
Ford's commercial arm, Ford Pro, is generating stable cash flow while management levers cost cuts and an emerging Ford Energy business provide re-rating catalysts. Valuation metrics (price-to-sales ~0.31, price-to-free-cash-flow ~6.2) leave room for upside if Ford can sustain margin improvement and monetize energy and BESS ambitions. We favor a mid…
NIO's latest quarter and delivery guidance point to improving unit economics. With a $12.6B market cap, elevated liquidity, and technicals near oversold, this is a pragmatic long trade: entry $5.20, stop $4.40, target $7.00 over a mid-term 45 trading day horizon.
Navios Maritime Partners (NMM) is trading below book with a market cap of $2.13B, single-digit P/E (6.3) and a large contracted revenue backlog. Combine that with bullish technicals and a recent bond program to shore up liquidity, and you get a mid-term trade with defined risk/reward: entry $74.50, target $88.00, stop $67.00 - horizon: mid term (45…
V2X (VVX) has been weighed down by a large private-equity shareholder exit. That overhang looks largely cleared after the March disposition, leaving a mid-cap defense contractor with a $4.6B multi-year contract, improving adjusted earnings and free cash flow. At $73.97 the stock trades at ~26x earnings and EV/EBITDA ~10x on a market cap of $2.32B. …
Apple's business is still huge and cash-generative, but market pricing and three structural risks - valuation stretchedness, AI & services disruption, and geopolitical/China fragility - create a viable path for AAPL to fall out of the Magnificent 7 by the end of 2030. This is a tactical short idea with a clear entry, stop, and target for a long-ter…
Teva is moving beyond a pure generics identity. A $700M acquisition of Emalex (ecopipam), a confirmed buyback and cost-savings plan, and visible cash generation create a tactical long opportunity into H2 2026 regulatory milestones. Trade plan with entry at $34.00, stop at $29.00 and target $42.00 for a long-term (180 trading days) horizon.
